Abstract
Administration of a gonadotropin-releasing hormone (GnRH) agonist at the preovulatory phase is an option for triggering ovulation in assisted reproductive technology cycles. The aim of this work was to investigate the pattern of prolactin secretion after the administration of a single dose of GnRH-agonist at the preovulatory phase. Descriptive study at a tertiary referral center. Fifteen normally ovulating patients undergoing ovarian stimulation for intrauterine insemination were studied. Ovarian stimulation was carried out using human menopausal gonadotropin (intramuscular 75 IU daily). When at least one follicle reached 17 mm (observed echographically), 0.5 mg of buserelin acetate was administered. Blood samples were taken to determine prolactin concentrations, at the time of agonist injection and 4, 8, 12, 24 and 48 hours later. A statistically significant increase in serum levels of prolactin was observed 4, 8 and 12 hours after GnRH-agonist administration, with a peak at 8 hours. The administration of a single dose of GnRH-agonist at the preovulatory phase in patients undergoing ovarian stimulation performed with human menopausal gonadotropin causes a significant increase in serum prolactin levels.
Highlights
In protocols for ovarian stimulation for the treatment of infertility, gonadotropinreleasing hormone (GnRH) agonist analog has been used as an alternative to human chorionic gonadotropin for triggering ovulation.1 Administration of the analog at the preovulatory phase induces an endogenous surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and the effect may be more physiological than that of exogenous human chorionic gonadotropin.2 This study was designed to investigate whether the pattern of prolactin secretion is affected by the administration of gonadotropin-releasing hormone (GnRH)-agonist
The administration of GnRH-agonist at the preovulatory phase to trigger the ovulation process causes a significant rise in serum prolactin concentrations
The administration of a single dose of GnRH-agonist at the preovulatory phase in patients undergoing ovarian stimulation performed with human menopausal gonadotropin causes a significant increase in serum prolactin levels
Summary
In protocols for ovarian stimulation for the treatment of infertility, gonadotropinreleasing hormone (GnRH) agonist analog has been used as an alternative to human chorionic gonadotropin for triggering ovulation.. Administration of the analog at the preovulatory phase induces an endogenous surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and the effect may be more physiological than that of exogenous human chorionic gonadotropin.. This study was designed to investigate whether the pattern of prolactin secretion is affected by the administration of GnRH-agonist
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
